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 Reliable and reproducible biomarker analysis is the main focus of current clinical 
diagnostic approaches being developed for the sensitive detection and quantification of 
biomarkers in bodily fluids. Currently used tools are being revised for better analytical 
performance that overcomes the drawbacks of inaccurate results. Surface plasmon 
resonance imaging is rising quickly as an affinity-based optical biosensor that 
demonstrates numerous improvements to the sensor surface design and sensitivity for 
label-free and real-time biomarker analysis. In this work, our goal is to develop a more 
sensitive analytical method for the enhanced detection of the human growth hormone 
(hGH) in serum, multiplex detection of disease biomarkers (KIM-1 and HMGB-1) 
simultaneously in buffer using a sandwich-amplification assay, and small molecule-
progesterone sensing using a novel aptasensor. Our goals were met by ensuring a 
homogenous and specific immunosensor for detecting hGH at very low concentrations (> 
9.1 pg/mL), substituting random antibody attachment with a site directed immobilization 
to the sensor surface for multiplex detection of two disease biomarkers down to 5 pg/mL 
levels in buffer, and further increasing the sensitivity of progesterone biosensor by 
exploiting x-aptamer technology for highly selective detection of progesterone (> 1 nM) 
in buffer.
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CHAPTER I 
	
INTRODUCTION 
	
	
Biological markers also known as biomarkers are present in all body parts and 
tissues. The detection of biomarkers in bodily fluids has been the goal of clinical 
diagnostic techniques mainly in order to obtain a better understanding of the 
physiological processes related to disease progression as well as the evaluation of the 
efficacy of therapeutic treatments. This has led to the development and continuous 
improvement of proteomic technologies that can identify novel biomarkers in a reliable 
and sensitive manner. Gel electrophoresis [2], mass spectrometry [3], matrix-assisted 
laser desorption/ionization mass spectrometry (MALDI-MS) [4], real time polymerase 
chain reaction (PCR) quantification of protein biomarkers [5], and antibody-array assays 
such as the common enzyme linked immunosorbent assay (ELISA) [5] have become 
widely used direct analysis tools that assess biomarker activity and concentration in body 
fluids. These technologies have served in the validation of biomarker activity and have 
provided quantitative data for specific target proteins; however, better alternatives have 
emerged to meet the challenges of developing better quality and more reproducible 
assays.  
Optical singleplex and multiplex detection of critical biomarkers in serum or 
blood is one example, which has been shown to provide excellent sensitivity and 
reproducibility [6]. The specificity and sensitivity of this detection method has proven to 
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be suitable for clinical use, as accurate measurements have been achieved. Surface 
plasmon resonance imaging lies at the forefront of optical tools that can detect and study 
biomarkers in a label-free and real-time manner.   
I.1 SPRi in the Detection of Clinical Biomarkers 
Surface plasmon resonance imaging (SPRi) is one the most popular optical 
technologies used to study biomolecular interaction at the nanoscale level on a metal-
coated surface. This tool is characterized by its label-free and real-time nature in the 
quantitative analysis of biomolecular processes. The inherent properties offer a major 
advantage over other widely used techniques, as it is capable of enhancing the sensitivity 
and specificity of the detection process.  The sensing capabilities of this technology have 
been extended to analyze a range of biomolecular recognition events and binding types. 
Protein- protein [7-10], protein-DNA [11, 12], protein-antibody [13, 14], protein-cell 
[15], antibody-cell [16, 17], toxin-receptor [18] have been at the focus of the many 
applications of this platform.  
I.2. Principle of Operation of SPRi Sensors 
SPRi biosensors require the immobilization of a ligand (antibody, protein, DNA, 
toxin, bioreceptor…. etc.) onto a thin metal-coated surface (mostly gold) as it is a good 
starting point for further surface modifications. This optical technique utilizes the 
changes in refractive index at the interface between the metal surface and the medium of 
interaction as means for the detection of the analyte in solution (Figure 1.1 A&B). The 
sensing mechanism utilizes an incident monochromatic light that hits the sensor surface, 
a detector that collects the resulting reflected light and a CCD camera that generates a 
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real-time contrast image. The sensor surface consists of a high index prism, coated with a 
chromium adhesion layer (5 nm) and a gold layer (50 nm) where the ligands of interest 
are immobilized. At a specific incident angle known as the resonance angle, the 
impinging light excites the free electrons in the gold layer; resulting in an evanescent 
field (up to ~400 nm thick); which exponentially decays from the sensor surface. And 
this in turn leads to a minimum intensity in the reflected light. The surface plasmons thus 
created are sensitive to perturbations in the refractive index of the surrounding medium; 
and a detector measures these alterations as changes in the reflectivity signal. The SPRi 
apparatus also allows a real-time visualization of the sensing surface for multi-array 
purposes by intercepting the reflected light with a CCD camera to provide a contrast 
image representing the biomolecular interactions at the surface [19].   
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Figure 1.1. The SPRi Biosensor Setup Based on the Kretschmann Geometry. (A) 
The light incident on the metal surface excites the surface plasmons causing a dip in 
the reflected light. (B) A CCD detector collects the reflected light and generates a 
digital difference image reflecting the binding events on the sensor surface. Bright 
spots represent regions of specific-biomolecular interaction and dark regions 
represent the absence of biomolecular interaction. 
	
	
I.3. SPRi Sensor Surface Optimization 
At the heart of SPRi biosensors lies the sensor surface design as the primary 
building block in assay development. In fact, the sensor surface has a tremendous role in 
determining the performance of the biosensor in different applications.  Hence, it is 
crucial to develop optimal surface chemistries that can mimic biological environments 
while maintaining the functionality of immobilized ligands. The metal-coated sensor 
surface serves as the substrate that is treated with various chemistries to enable the 
linking of ligands to the biosensor surface. There are two major aspects to take into 
account when a surface is treated for analyzing biomolecular interactions. First, a proper 
surface architecture is important for a qualitatively and quantitatively efficient 
A B
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immobilization of capture ligands. In this process, steric hindrance, amount of ligand 
immobilized, biological activity, and orientation of ligand are all influenced by the 
selected nanostructured sensor surface. The second factor in the design of label-free 
assays is the homogeneous bioinertness of the sensor surface that minimizes the non-
specific adsorption of protein and other macromolecules present in complex bodily fluids. 
This process is known as surface blocking; hence, the ratio of specific signal to non-
specific signal will be high.  
I.4 Direct versus Sandwich-Amplification Detection  
 The detection of biomolecular events using SPRi can be carried out by two main 
strategies, direct or indirect. The direct mode of detection as the name implies, involves 
the detection of biomolecules in solution upon the interaction with the immobilized 
ligands in the solid phase. This is performed without the need for secondary markers or 
labels. On the other hand, indirect detection (sandwich amplification assay) involves the 
introduction of signal enhancing probes that bind to the analyte bound to the immobilized 
ligands in order to improve the sensitivity of the assay. Therefore, signal amplification 
probes have extended the application of SPRi to include small analyte resulting in 
ultrasensitive assays. 
 In the following chapters, we demonstrate the development of ultrasensitive SPRi 
sensor assays based on specific monoclonal capture antibodies and x-aptamers for the 
detection of different biological molecules. In these studies, we incorporated the label-
free, real-time, and multiplexing capabilities of SPRi with signal amplification probes 
(near-infrared quantum dots) for achieving ultrasensitive limits of detection of 
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biomolecules in serum and buffer. Moreover, we introduced significant improvement in 
sensor surface design, which is a critical step in the development of a reliable assay.   
In our first work, we developed a SPRi immunoassay and introduced signal 
amplification probes for the detection of the recombinant human growth hormone (rhGH) 
in serum. The ultrasensitive detection of hGH is essential as it is linked to numerous 
growth disorders and used by athletes as a doping agent for enhanced physical 
performance. The hGH immunosensor was developed by the covalent attachment of 
monoclonal hGH antibodies to the sensor surface and by further blocking the surface 
using bovine albumin serum (BSA). Blocking the sensor surface was performed to 
minimize the non-specific adsorption of proteins and biomolecules present in serum. 
Upon successful optimization of sensor design, direct detection of hGH at different 
concentrations in serum was performed and the limit of detection was determined to be 
3.6 ng/mL. Further addition of signal amplification probes, pre-functionalized with hGH 
secondary antibodies, allowed a detectable signal to be achieved at lower concentrations 
with a limit of detection of 9.1 pg/mL. The results of these two assays were compared to 
an hGH ELISA assay performed at different concentrations in serum which resulted in a 
LOD of 1 ng/mL. As can be deduced, the conventional analysis tool (ELISA) was similar 
in sensitivity to the direct SPRi measurements. However, the enhancement in sensitivity 
was accomplished with the incorporation of amplification probes to the immunoassay 
(Nano-SPRi). The ultrasensitive capability in addition to reproducibility and short 
detection time impart the robustness and novelty to the Nano-SPRi assay over 
conventional ELISA assays. The results achieved with this immunosensor have led to a 
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multiplex study, which assessed the multi-target detection of disease related biomarkers, 
KIM-1 and HMGB-1 in buffer.  
In the second study, we employed a specific antibody-based SPRi assay in 
combination with signal enhancers for the ultrasensitive measurement of HMGB-1 and 
KIM-1 in a singleplex and multiplex  manner. The immunosensor surface was designed 
differently from the one previously reported for the purpose of enhancing the sensitivity 
and reproducibility of the platform. We adopted a non-covalent attachment approach for 
monoclonal KIM-1 and HMGB-1 capture antibodies to the sensor surface. We chose to 
pursue with the non-covalent attachment of antibodies because this results in well-
oriented ligands in comparison with the amine coupling of antibodies, which leads to 
random immobilization on the sensor surface. The surface was further blocked using a 
combination of BSA and polyethylene glycol (PEG) to decrease the non-specific 
adsorption of proteins. As a result, a robust immunoassay was obtained and used in 
combination with signal enhancers for the singleplex and multiplex analytical 
measurement of HMGB-1 and KIM-1 with a limit of detection of 5 pg/mL in buffer.  
Our next approach aimed at performing small molecule sensing using a 
nanoenhanced SPRi aptasensor. Progesterone, a steroid hormone responsible for multiple 
reproductive processes in the female body was the target analyte in this assay. Its 
detection can assist in the early diagnosis of pregnancy as well in fertility investigations. 
For the purpose of the ultrasensitive detection of progesterone, specific x-aptamers were 
developed as the capture ligands and nanoenhancers were introduced again to assay 
procedure. The capture ligands were immobilized on the senor surface and progesterone 
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levels was directly measured in buffer as well as indirectly to achieve a LOD of 1 nM. As 
a result, this work introduced a novel, reliable, and sensitive aptasensor that detected 
progesterone at ultra-low concentrations.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 9
CHAPTER II 
	
REVIEW OF THE LITERATURE 
	
	
II.1. Sensor Surface Development in SPRi Platforms    
 The performance of a biosensor is highly influenced by the surface development, 
which represents the primary building block in the assay design. In this step, it is critical 
to design a reproducible platform while retaining the activity of biological molecules. 
This process begins with a bare gold surface, which manifests a high affinity for soft 
electron pair donors such as thiolated compounds. Hence, the thiol-gold bonding 
character is a widely employed surface treatment method in self-assembly because the 
thiolated compounds adsorb spontaneously on the metal surface and serve as a strong 
support for the anchored ligand of interest.  
II.1.1 Surface Chemistries and Immobilization Methods      
Sensor surface development can be accomplished by two methods, either by 
utilizing thiolated linkers (alkanethiols) [20-22] to immobilize the ligand or a thiol-
modified ligand directly attached to the sensor surface [23, 24]. For example, Mannelli et 
al. developed an efficient sensor to monitor the hybridization of DNA anchored on the 
metal surface [25] by functionalizing the bare gold surface with 11-mercaptoundecanoic 
acid-poly (ethylenimine) and exposing the amine-reactive surface to an extravidin 
solution, which is further allowed to support the biotinylated DNA [26, 27] by the strong 
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affinity avidin-biotin interaction. Similarly, amine terminated alkanethiols were reacted 
with a bare gold surface by the thiol ends and to chicken ovalbumin and immunoglobulin 
G by the amine terminated ends. These biomolecules were used as models for different 
glycoproteins that could potentially be identified and analyzed using SPRi [28]. In 
addition, thiol modified ligands can be directly attached to the sensor surface without the 
need of linkers, and Manera et al. have immobilized thiolated DNA onto lithographically-
patterned gold surface to monitor the hybridization of the 35S promoter oligonucleotide 
probe [27] as a way to detect for genetically modified organisms inserted into a host 
genome. Similarly, Song et al. were able to detect two specific genes of Arabidopsis 
thaliana leaf extract at attomole concentrations using thiol-modified DNA probes [29]. 
 Another approach utilizing ligand attachment in antibody immobilization [30, 31] 
involves the activation of carboxyl groups of alkanethiols directly adsorbed onto the 
surface by 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)/ N-
Hydroxysuccinimide (NHS). This activation step yields an amine-reactive surface via 
reactive esters [32] and forms a supporting layer for amine-containing compounds. For 
example, an immunosensor was developed for early cancer diagnosis by selectively 
identifying potential cancer biomarkers using an anti-activated leukocyte cell adhesion 
molecule/CD 166 (ALCAM) and anti-transgelin-2 (TAGLN2) immobilized on an 
EDC/NHS activated surface [33].  
A variety of surface chemistries have been developed for SPRi-based 
applications. Advances have also emerged to improve the performance of biosensors; for 
instance, amine coupling of specific antibodies with amine-reactive surface is not optimal 
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for reliable and reproducible results in immunosensors. This is mainly due to the random 
attachment of ligands onto the surface resulting in an uncontrolled orientation of the 
ligand, and a reduction in the biological activity of the biomolecule (Figure 2.1). With 
these limitations in mind, alternative strategies were needed and one study was able to 
take advantage of binding properties of protein G produced by genetically engineered 
Streptococcus bacteria which introduces cysteine residues at specific sites of the protein 
[34]. Cysteine residues, which contain thiol groups, can adsorb on the gold surface and 
form a layer of protein on the sensor surface. Protein G has a specific binding site for the 
fragment crystallizable (fc) region of antibodies; hence, participating as an affinity 
receptor for antibody immobilization (Figure 2.2). This approach results in well-oriented 
antibodies and reproducible sensing platforms with enhanced sensitivity [35].   
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Figure 2.1. A Demonstration of Two Strategies for Antibody 
Immobilization. (A) Random antibody immobilization (A) and site-
directed antibody immobilization (B) [1]. 
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Figure 2.2. A Scheme Representation of the Immobilization of IgG Antibodies to a 
Protein G (cysteine-tagged) Coated Surface 1. 
	
	
II.1.2 Peptide and Antibody-Based SPRi Arrays    
 The study of antibody-antigen interaction can be achieved using SPRi-based 
microarrays and has been reported in numerous studies. In one study, chicken polyclonal 
antibodies specific for M. Synoviae were assessed in a rapid, label-free and peptide-chip 
SPRi platform. The sensor surface was immobilized with lipoprotein major surface 
protein (MSPB) and hemaglutinin MSPA as the specific antigens responsible for the 
serodiagnostic measurement of anti-MSPA levels in chicken serum [36]. Ro et al. 
constructed another peptide-based assay for the analysis of protein-protein interaction for 
a better understanding of these basic cellular regulatory processes. Human papillomavirus 
(HPV) was chosen as the model study and the interaction of surface attached-HPV E6AP 
																																																								
1	Reprinted  “Lee, J.M., et al., Direct immobilization of protein g variants with various 
numbers of cysteine residues on a gold surface. Anal Chem, 2007. 79(7): p. 2680-7”. 
Copyright (2007) with permission from American Chemical Society.	
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with P53 and E6 was assessed resulting in a detectable and quantitative SPRi response 
that reflects the binding events between these proteins [37].  
 In response to the need for reliable methods that can detect food borne pathogens, 
and in specific staphylococcal enterotoxin A (SEA), a SPRi immunosensor was 
functionalized using a self-assembled monolayer (SAM) onto which anti-SEA were 
directly immobilized. This platform exhibited a specific and sensitive detection of the 
toxin in buffer and in both phosphate buffer and milk at a concentration range of 100-
1000 ng/mL as shown in Figure 2.3 [38].  
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Figure 2.3. (A) The Different SPRi Sensorgrams Representing the Response (angle 
shift) Obtained with the Different Concentrations of SEA to an Anti-SEA 
Functionalized Surface. (B) A Concentration Standard Curve of the SPRi Response 
(angle shift) versus the Concentrations of SEA Interacting with Anti-SEA 
Functionalized Surface in Phosphate Buffer 2. 
 
 
In addition, human inflammation markers in the blood serum such as the C-
Reactive Protein (CRP) represent a classical target in many SPRi studies due to the 
																																																								
2	Reprinted from Sensors and Actuators B: Chemical SPR-based immunosensor for 
determining staphylococcal enterotoxin A, 136, Tsai, Wen-Chi, Li, Ie-Chin, 8-12. 
Copyright (2009), with permission from Elsevier. 
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enhanced sensitivity and selectivity of this detection technique [39-42]. Meyer et al. 
investigated the potential of an anti-CRP immunosensor for the direct measurement of 
CRP levels in buffer while taking advantage of the kinetic analysis to determine the 
association and dissociation rates of CRP from two different antibodies [43]. The 
detection of CRP was performed by the assistance of a detection antibody (C2) that binds 
the already surface bound CRP (Figure 2.4).   
 
 
Figure 2.4. A Scheme Representing the Surface Setup of the Gold Sensor and the 
Binding Events of CRP Occurring on the Surface. A biotin-streptavidin binding 
allows the attachment of the selective anti-CRP to the surface. A detection antibody 
(C2) is injected following the addition of CRP forming the reported detection signal 
3. 
	
	
II.1.3 Nucleic Acid-Based SPRi Arrays  
 SPRi has gained increased interest as a promising analysis tool for the detection, 
quantification, and understanding of nanoscale biomolecular events occurring on the 
																																																								
3	Reprinted from Biosensors and Bioelectronics, SPR-based immunosensor for the CRP 
detection—A new method to detect a well known protein, 21, Martin H.F. Meyer,Markus 
Hartmann,Michael Keusgen, 1987-1990., Copyright (2006), with permission from 
Elsevier.	
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metal surface of a biosensor. This has led to numerous studies in the area of DNA 
identification and interactions with complementary biomolecules. For example, Corn’s 
research group successfully developed innovative surface treatments to optimally attach a 
variety of oligonucleotides (DNA and RNA) to the metal surface for analysis. Assessing 
the binding and catalytic properties of the repair enzyme DNA N-glycosylase and the 
binding of repair proteins to damaged regions of DNA was accomplished by an array of 
oligonucleotides [44]. Single-stranded oligonucleotide microarrays were also employed 
to detect the of Roundup Ready soybean lectin gene sequences by real-time monitoring 
of the hybridization of the target PCR products and DNA or PCR-generated probes [45]. 
DNA based microarrays have proven capable of differentiating between close nucleotide 
sequences which has extended their application to assessing gene mutations for gaining a 
better understanding of cystic fibrosis [46].  
II.2. Multitarget Detection Using SPRi Microarrays  
SPRi assays are characterized by their microarray ability, which entails a highly 
versatile analysis tool for the simultaneous detection of multiple interactions on the 
sensor surface in a high-throughput manner. This sensing capability successfully meets 
the future needs of medical diagnostics and is made possible by the imaging component, 
which allows the selection and identification of numerous spotted ligands on the surface 
for analysis. Piliarik et al. developed a multiplex platform for the screening of protein 
biomarkers involved in cancer diagnosis and were able to achieve significantly sensitive 
limits of detection as low as ng/mL concentrations in blood plasma [40]. The platform 
developed for this purpose uniquely combined specific antibodies and DNA spotted on 
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the surface. The surface was primarily functionalized with thiolated oligonucleotide 
sequences and the specific antibodies were immobilized in a well-directed manner by 
conjugation to an oligonucleotide sequence that is complementary to the spotted 
oligonucleotide sequence, which can directly hybridize to the sensing area. Furthermore, 
The multiplex monitoring of three allergens in milk was performed using a biosensor 
immobilized by the 3 allergens, α-lactalbumin, β-lactoglobulin and casein and specific 
antibodies for each flowing above the surface. This analysis assisted in obtaining the 
avidity of the interaction by monitoring the kinetics of the association and dissociation of 
the antibody-allergen in real-time [47]. The performance of SPRi multi-target arrays was 
also tested for the immunodetection of antimicrobial drugs in milk residue in order to 
provide a better assessment of consumer health risks [48].  
The implications of this sensing capability have also extended to detect small 
molecules, which can be very challenging in SPRi based platforms. Mycotoxins are one 
example and their interaction with complementary antibodies was assessed in one study 
[49] to achieve detectable signals at low concentrations. The low limit of detection 
(pg/mL levels) was obtained due to the use of gold nanoparticles as signal enhancement 
probes that were added as the last step of the assay shown in Figure 2.5.  
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Figure 2.5.  A Schematic Representation of the Immobilized Mycotoxins and the 
Selective Detection Using Monoclonal Detection Antibodies Followed by the Signal 
Enhancement Due to the Introduction of Gold Nanoparticles 4. 
	
 
II.3. Signal Amplification Strategies in SPRi Assays 
 Currently, SPRi is used for industrial as well as academic research in screening 
biomolecular activity due to its label-free and real-time analysis; however, this tool still 
faces some limitations and there is room for improvement. This is mainly manifested in 
small molecule sensing imposed by the mass loading effect as the major factor causing 
the change in reflectance reported as the SPRi response. As a result, researchers have 
dedicated time and effort to investigating the optimization of the platform and employing 
signal enhancers [50] that would indirectly amplify the SPRi response as a method to 
increase the sensitivity of the platform. Numerous approaches have been reported that 
																																																								
4	Reprinted from the Journal of Colloid and Interface Science, Sensitive detection of 
multiple mycotoxins by SPRi with gold nanoparticles as signal amplification tags, 431, 
Hu, W., et al., 71-76., Copyright (2014), with permission from Elsevier.	
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utilize metal nanoparticles as indirect labels. Examples include gold nanoparticles [51, 
52], magnetic nanoparticles [53], and quantum dots [54, 55]. 
 Malic et al. were one of the first to apply quantum dots as amplification labels to 
enhance the diagnosis potential of SPRi-based platforms. The platform was designed for 
the detection of single stranded DNA (ssDNA) and a cancer biomarker, prostate-specific 
antigen conjugated to antichymotrypsin (PSA-ACT). In both immunoassays, the addition 
of the near infrared quantum dot complexes resulted in significant enhancement; 25 fold 
enhancement for ssDNA with a limit of detection (LOD = 100 fM) and 50 fold for PSA-
ACT (LOD = 100 pg/mL). An important finding of this work was the noticeable 
difference between the amplification effect of 800 nm QDs whose emission wavelength 
is the same as the emission wavelength of the light source used to excite the surface 
plasmons of the gold layer the remaining different sized QDs. The resonant coupling 
between the emitting 800 nm QDs and the propagating surface plasmons as well as the 
large mass of these nanoparticles were two reasons responsible for the signal 
amplification effect [55].  
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CHAPTER III 
	
COMPARATIVE ANALYSIS OF HUMAN GROWTH HORMONE IN SERUM  
 
USING SPRI, NANO-SPRI AND ELISA ASSAYS 
	
	
III. 1 Introduction  
Human growth hormone (hGH) is a 191 amino acid peptide (22 kDa) produced by 
the pituitary gland and directly released into the bloodstream. Interactions between the 
hypothalamic peptide growth hormone-releasing hormone (GHRH) and somatotropin 
induce pulsatile secretions of hGH. As a result, levels of hGH vary from highs in the 50-
100 ng/mL to lows in the 0.03 ng/mL range [56]. Deficiency or excess of hGH in the 
body can provoke a wide range of abnormal physiological symptoms. For example, 
excess levels of hGH can lead to gigantism [57] and diabetes [58] . Depleted levels of 
hGH cause low blood sugar in newborns, and weak bone density and depression in adults 
[59].  
The administration of the recombinant form of hGH (rhGH) improves lean 
muscle mass while reducing body fat. As such, this substance became the drug of choice 
for professional and amateur athletes as it improves physical strength that confers an 
advantage in competitive sports. rhGH is banned by the World Anti-Doping Agency 
(WADA) [60, 61] and much effort by international researchers has been focused on 
developing tests that can detect its presence or anabolic effect. Enzyme-linked 
immunosorbent assay (ELISA) has been the preferred method for the determination of 
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hGH in whole blood [62]. Although, ELISA is a reliable technique offering good 
sensitivity and selectivity, it is relatively time- and labor-intensive. In addition, ELISA 
relies on the indirect detection of hGH by employing enzymatic tags. In contrast, surface 
plasmon resonance (SPR) permits detection of hGH directly without the use of labels in 
real time. The detection principle behind SPR involves a sensing surface consisting of a 
prism that is coated with a thin metal layer (gold or silver); when a monochromatic 
polarized light interacts with the metal surface, “surface plasmons” are generated. The 
binding of an analyte to a surface receptor immobilized on the metal surface perturbs the 
resonance conditions resulting in a shifted resonance dip, which can then be correlated to 
the analyte concentration. SPR-based biosensors are now commercially available that 
offer a real-time, label free technique to monitor biomolecular binding events and 
biochemical reactions [63-65]. More recently, SPRi was developed in response to the 
need for multiplexing (i.e. monitoring multiple binding events simultaneously), which 
was not possible in classical SPR biosensors. Thus, SPRi has emerged as a tool to 
monitor several binding events simultaneously. Current SPRi systems are based on 
microscopic imaging of a surface which is excited with light at a specific angle and 
wavelength [65]. The image is then captured onto a charge-coupled device (CCD) array.  
To date, there have been a few SPR-based assays developed to detect hGH [66-
69]. One particular strategy, known as the isoform method [70], relies on the detection of 
the ratio of 22 kDa hGH to total hGH, as non-22-kDa endogenous levels drop after 
exogenous rhGH administration. Recently, de Juan-Franco et al. [66] reported on the 
development of a SPR-based immunosensor for the selective detection of the 22 kDa and 
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20 kDa hGH isoforms in human serum samples. Monoclonal antibodies specific to each 
isoform were immobilized directly on the gold sensor permitting the measurement of 
both isoforms simultaneously in a single injection with a limit of detection at 0.9 ng mL-1. 
Alternatively, SPR has been used to screen antibodies with high specificity to hGH [68]. 
If the concentration of target analyte falls below the SPRi system’s limit of detection (< 
nM), one has to resort to amplifying the SPRi signal via the utilization of nanoparticles 
(Nano-SPRi). Such SPR-based amplification has been well documented in the literature 
[55, 71-73] for various types of analyte and surfaces.  
In this work, the analytical potential of SPRi and Nano-SPRi based biosensors 
was examined, particularly for the detection of rhGH in spiked human serum, and 
comparison of its detection capability directly to ELISA. The following parameters will 
be reviewed and considered: detection time, sensitivity, kinetic profile, reproducibility 
and specificity. 
III.2 Methods 
III.2.1  Prepare SPRi Chip for Antibody Array 
A bare gold biochip is cleaned by sonication in a stabilized piranha solution (3:1 
concentrated sulfuric acid to 30% hydrogen peroxide) for 90 minutes at 50 C. This is 
followed by rinsing, sonication with water for 5 minutes, rinsing with ethanol and finally 
dried with nitrogen stream. The clean gold chip is then placed in an UV/Ozone chamber 
(30 mins) to remove any contaminants. The surface functionalization follows by a 
microwave radiation assisted procedure. The first step involves reacting the surface with 
an 11-mercaptoundecanoic acid (11-MUA) solution (34 mM, in pure ethanol) under 
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microwave radiation (50 W and 50 C) for 5 minutes. A sequential thorough ethanol and 
water rinse step follows this reaction.  The second step reacts the carboxyl groups of 11-
MUA with a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) solution (65 mM in 
ultrapure water) under the same microwave conditions (50 W and 50 C) for 5 minutes. 
The chip is then rinsed with ultrapure water to ensure the removal of unreacted 
chemicals. The third reaction involves another microwave irradiation (50 W, 50 C, for 5 
mins) of a N-hydroxysuccinimide (NHS) solution (40 mM in ultrapure water). And the 
last step involves blocking the sensor surface with a polyethylene glycol (PEG800) 
solution (250 µM in ultrapure water) under microwave irradiation (50 W, 50 C, for 5 
mins) and then rinsed with an ultrapure solution prior to immobilizing the anti-rhGH 
antibody. Microwaving PEG800 on the surface of the sensor is performed as a blocking 
step to prevent non-specific binding of serum proteins and quantum dot complexes later 
used in the experiment. This is achieved by PEG800 reacting with non-occupied bare 
gold sites on the chip. 
III.2.2  Immobilization of Antibody on Functionalized Chip 
A solution of anti-rhGH antibody (15 g/mL) and negative control (15 g/mL) 
solution of anti- Immunoglobulin G (anti-IgG) are prepared in a 10% glycerol phosphate 
buffer solution (PBS, 10 mM) solution. Both samples are then loaded to two separate 
wells in a 384 well plate. 
An array pattern is designed using the LabNext microarrayer (4x7 quadrants for 
each sample) and the ligands are spotted on the chip using a 500 m Teflon tipped pin. 
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The sensor chip is allowed incubation time of 2 hours at room temperature and under a 
humid atmosphere of 75% or greater. Finally, prior to carrying out the SPRi experiment, 
the sensor chip is rinsed and soaked in ultrapure water and dried with nitrogen stream.  
III.2.3 SPRi Experiment Setup and Blocking 
The SPRi Lab+ instrument is initiated and the sensor chip is loaded to its position 
in contact with the flow cell inside the apparatus. The sensor chip is rinsed with ultrapure 
water initially. Following this loading step, a low salt PBS buffer (10 mM phosphate, 150 
mM sodium chloride, pH 7.4) is flown above the surface at a rate of 1 mL/min for a total 
of 5 mL and then the flow rate is slowed down to 20 µL/min and allowed to stabilize for 
20 minutes. Prior to analysis, a set of experimental conditions is chosen and one of which 
is the selection of the highly contrasted difference image of the sensor chip. This digital 
image provides a real time visualization of the surface and allows the operator to select 
and define the areas of interest on the surface (400 µm spots). Another step is to trace the 
plasmon curves done by the instrument and choosing a working angle at which the 
highest slope in reflectivity curves is obtained.  
The next step introduces the first blocking agent, a bovine serum albumin (BSA) 
solution (100 µg/mL) prepared in the running buffer. BSA is injected to covalently bind 
to the amine reactive surface, the remaining unbound BSA will wash off the surface 
through buffer rinse. A solution of sodium acetate (10 mM) is injected and a high salt 
PBS (10 mM phosphate, 750 mM sodium chloride, pH 7.4) injection follows to wash the 
surface. The amine reactive surface is further deactivated by ethanolamine (1 mM). 
Another surface wash by sodium acetate (10 mM) is performed after this step. 
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Ultimately, preceding the successful blocking and deactivation of the surface, the running 
buffer is switched to a 10 mM PBS with 50 µg/mL BSA solution and a flow rate of 250 
µL/min for a total of 5 mL.  BSA (50 µg/mL) is added to the running buffer for 
additional blocking of the surface by non-covalently occupying the non-specific sites and 
this is done to further reduce non-specific binding of serum proteins to the surface.  
Finally, the running buffer flow rate is slowed down to 5 µL/min for the kinetic 
monitoring.  
III.2.4 SPRi Detection of Human Growth Hormone 
 Initially, a solution of a set concentration of rhGH (30,000 pg/mL; 250 pg/mL; 25 
pg/mL; 2.5 pg/mL and 0.25 pg/mL) in 10% serum is prepared and diluted in PBS 
containing 1 mg/mL BSA. And a 2:1 solution of biotin labeled anti-rhGH detection 
antibodies (6 µM) and streptavidin coated near infrared quantum dots (1 µM) is prepared 
and incubated for 30 min for effective coupling. Then the rhGH prepared sample is 
injected into the flow cell and the SPRi HORIBA software records the kinetic monitoring 
of the interaction. Since this interaction results in some non-specific interaction of the 
serum proteins, the surface is washed with a sodium chloride (450 mM in running buffer) 
solution prior to the signal amplification step. The previously prepared solution of anti-
rhGH detection antibodies and quantum dots is diluted to a concentration of 10 nM (2:1) 
with running buffer (PBS with 50 µg/mL BSA) and injected into the flow cell. Following 
the injection of the rhGH spiked human serum and quantum dot enhancer, an increase in 
reflectance change occurs due to the amplified shift of the plasmon curves. This results in 
a difference image showing a gray scale image correlating to the signal of on the chip. 
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III.2.5 SPRi Data Analysis 
The kinetic data is imported into a data analysis program and the SPRi signal (% 
Reflectivity) is plotted versus time (s) to determine the difference between the anti-rhGH 
and negative control antibody spots after the high salt wash.  
III.2.6 ELISA Protocol  
The ELISA assay was performed using a commercially purchased kit (Invitrogen) 
and the manufacture protocol was followed for assay preparation and analysis. All assay 
components included in the rhGH ELISA kit are stored at 2-8 C when not in use. This 
includes the anti-rhGH antibody coated well plates, standards (0-5) in sheep serum, 
controls (1 &2) in human serum, conjugate buffer, (200X) wash buffer, chromogen TMB 
(Tetramethylbenzidine) and stop reagent. Prior to assay setup, the anti-rhGH antibody 
coated 96-wells is warmed to room temperature and the desired number of 8-well strips 
for assay is removed while keeping the remaining wells sealed in the foil package to store 
at 2-8 C. The standards are prepared by reconstitution in 2 mL distilled water for 
standard #0, in 1 mL of distilled water for standards (1-5), and in 1 mL of distilled water 
for the controls (1&2). Below is a table of the corresponding concentrations of the 
standards and controls (Table 3.1). 
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Table 3.1. Concentrations of The Standards and Controls Included in the 
Commercial ELISA Kit 
	
Standards Concentration (ng/mL) 
0 0 
1 0.17 
2 0.94 
3 2.63 
4 10.4 
5 26.9 
Control #1 1.22 ± 0.33  
Control #2 4.97 ± 1.25  
 
The samples, which consist of the rhGH hormone in 10% human serum, are prepared at 
the following concentrations (Table 3.2). 
 
Table 3.2. Concentrations of the rhGH Samples Prepared in 10% Serum. 
	
Sample Concentration (ng/mL) 
1 0.025 
2 0.2 
3 0.5 
4 2.5 
5 10 
6 30 
 
 
The standards, controls and samples (50 µL) are added to each well (in triplicates) 
and the wells are sealed and incubated overnight at 4 C under gentle shaking. The plate 
is removed from the shaker the following day and allowed to warm to room temperature 
(15-20 mins) prior to proceeding with the assay. And the Anti-rhGH-HRP, conjugate 
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buffer, wash buffer (200x), chromogen TMB (tetramethylbenzidine), and stop reagent are 
all removed from the refrigerator and allowed to warm to room temperature as well.  The 
anti-rhGH-HRP is diluted 40x with the conjugate buffer and the wash buffer is diluted 
200x with distilled water.  Anti-rhGH-HRP conjugate (50 µL) is added into each well, 
and the wells are sealed and incubated at room temperature for 30 minutes while gently 
shaking. The solution is then decanted from the wells by inverting the plate, tapping it 
dry onto an absorbent tissue, and then washed with wash buffer (200 µL) into each well 
for three times. A solution of chromogen (100 µL) is then added into each well within 15 
minutes following the wash step and incubated for 30 minutes at room temperature in the 
dark while gently shaking. The solutions turned from colorless to blue. Finally, the stop 
reagent (100 µL) is added into each well causing the solutions to turn from blue to yellow 
and the absorbance of each well is read immediately at 450 nm using a microplate reader. 
The optical density of the rhGH in 10% serum samples is plotted versus the concentration 
of each sample.  
III.3 Results 
III.3.1 Schematic Representation of Direct and Amplified SPRi  
The performance of SPRi and Nano-SPRi (SPRi employing NanoEnhancers) was 
compared with ELISA for the detection of rhGH in a complex environment. The 
differences in the setup of these methods are described here briefly. For SPRi (direct 
detection, Figure 3.1), the capture antibody is immobilized on the surface and then the 
sample is injected and binding of analyte to the sensor surface is measured directly in real 
time and label-free manner. However, with Nano-SPRi (Figure 3.1), after the analyte 
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binds to the sensor surface, a consecutive injection is followed with quantum dots coated 
with detection antibodies to amplify the SPRi signal. The ligands (rhGH or IgG specific 
antibodies) were immobilized in an array format on the SPRi biochip. Target protein 
(rhGh) spiked in human serum was introduced to the sensor surface are directly detected 
(SPRi) and sequentially highlighted with NanoEnhancers (Nano-SPRi). 
 
 
Figure 3.1. A Schematic Representation Comparing Direct-Mode (SPRi) and 
Amplified-Mode. 
	
	
III.3.2 ELISA Setup and Analysis of RhGH in 10% Serum 
As for ELISA, the multiwell plates arrive already pre-functionalized with capture 
antibody and then the sample is introduced, the analyte of interest will bind. A detection 
antibody is introduced followed by substrate addition. The optical density is then 
measured at 450 nm. In this study, a commercial ELISA kit (Figure 2) was used to 
measure rhGH spiked in 10 % human serum.  
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Figure 3.2. A Schematic Representation of the ELISA Assay Procedure. rhGH 
protein (blue ovals) is introduced to wells that have been pre-functionalized with 
monoclonal antibodies (yellow) specific to rhGH. Non-specific interactions are 
eliminated by rinsing the wells with wash buffer followed by the introduction of a 
detection antibody prefunctionalized with horseradish peroxidase (HRP, purple). 
The solution will change in color after adding the substrate tetramethylbenzidine 
(TMB, gold). 
	
	
Figure 3.3 represents the titration curve of rhGH spiked in 10 % human serum and 
is plotted against the obtained OD at 450 nm. A good linear response was observed and 
the limit of detection was determined to be 1 ng/mL. The coefficient of variation 
(CV) was 6.5 % suggesting good reproducibility. 
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Figure 3.3. ELISA Data Analysis. Concentration of rhGH spiked in serum is plotted 
against the obtained OD at 450 nm. 
	
	
III.3.3 Direct Detection of RhGH in 10% Serum with SPRi 
Next, the detection of rhGH spiked in human serum was assessed with SPRi. 
Direct detection of rhGH resulted with the corresponding concentration gradient curve 
(Figure 3.4), each point represents the average value of the reflectivity difference 
calculated from three SPRi kinetic curves for each concentration. The limit of detection 
(LOD) was determined to be 3.61 ng/mL. The SPRi direct detection assay was highly 
reproducible as the CV of the assay was only 4.1 %. 
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Figure 3.4. Direct SPRi Detection of rhGH Spiked in 10 % Human Serum. The 
resultant normalized SPRi kinetic plot after the injection of various amounts of 
hGH spiked in human serum followed by the injection of a high salt buffer (dashed 
vertical line) to remove non-specific interactions. A concentration gradient curve 
representing the binding of various amounts of hGH spiked in human serum to the 
sensor surface that has been prefunctionalized with biotinylated hGH-specific-
Antibody. 
	
	
III.3.4 Amplified Detection of RhGH in 10% Serum with NanoSPRi 
To increase the sensitivity of the SPRi biosensor, NanoEnhancers (QDs pre-
functionalized with detection antibodies) are sequentially introduced to the sensor surface 
in order to highlight the presence of rhGH spiked in human serum. After background 
subtraction, the NanoEnhancers were able to amplify the biosensor response up to 7.9 %, 
however, with minimal signal change (Immunoglobulin G (IgG)-specific antibody, 0.38 
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% change in reflectivity; Figure 3.5 on controlled regions of interest. Imaging of the 
sensor surface revealed that only regions of interest that have rhGH-specific antibodies 
immobilized experience the largest contrast change corroborating directly with the kinetic 
sensorgram response.	
	
	
Figure 3.5. Detection of rhGH Using a Sandwich Assay Spiked in 10 % Human 
Serum. SPRi kinetic plot after the injection of rhGH (30 ng/mL) in buffer (10 mM 
PBS, 150 mM sodium chloride, pH= 7.4) onto a pre-functionalized chip with 11-
mercaptoundecanoic acid / rhGH-specific antibody and control IgG-antibody then 
blocked with BSA followed by the addition of detection antibody-coated quantum 
dots (NanoEnhancers). 
	
 
To demonstrate the practicability of the Nano-SPRi biosensor, the measuring 
range of rhGH in crude samples was assessed. An extended working range from 30,000 
pg/mL to 0.25 pg/mL resulted as a response to the addition of NanoEnhancers (Figure 
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3.6). It is worth noting that each point on the titration curve is averaged from three 
independent experiments. Consequently, the lower limit of detection was calculated to be 
9.20 pg/mL and the coefficient of variation was 20 %.  
 
 
Figure 3.6. Nano-SPRi Detection of hGH Spiked in Human Serum. Normalized 
SPRi kinetic plot representation of hGH_specific_Anti-QDs-amplified signal for 
human serum samples spiked with different concentrations of rhGH. A vertical 
dashed line (grey) represents the injection point of the running buffer. (b) A 
concentration gradient curve representing the binding of NanoEnhancers 
(hGH_specific_Anti-QDs) after the injection of various amounts of hGH spiked in 
human serum to the sensor surface that has been prefunctionalized with 11-
mercaptoundecanoic acid /hGH-specific antibody. 
	
	
III.3.5 Comparative Analysis of SPRi and NanoSPRi 
Next, the change that occurs in the SPR reflectivity curve as a function of the 
concentration was compared between the direct and the NanoEnhancer bioassay method 
(Figure 3.7). For the direct detection technique between 25 and 0.25 pg/mL, the signal 
started to plateau and this is not surprising as these concentrations fall below the LOD of 
3 ng/mL (Figure 3.7). Similarly, for the amplified technique, concentrations below the 
LOD of 9.2 pg/mL signal started to plateau and showed virtually no variation.  
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Figure 3.7. A Comparative Analysis of SPRi with Nano-SPRi. This bar graph 
depicts the percent change in reflectivity (%R) after introduction of rhGH spiked 
in human serum (direct detection) followed by the injection of NanoEnhancers 
(amplified detection) for 30,000 pg/mL, 250 pg/mL, 25 pg/mL, 2.5 pg/mL and 0.25 
pg/mL. 
	
	
III.3.6 Specificity Analysis of NanoSPRi Platform  
Furthermore, the specificity of the Nano-SPRi biosensor was assessed. Insulin-
like growth factor-1 (IGF-1) spiked in human serum was injected as a control since hGH 
stimulates the secretion of IGF-1 through the growth hormone receptor on the hepatocyte 
membrane. After the injection of the IGF-1 in serum, the NanoEnhancers were 
sequentially injected and the SPR signal response did not show any specific binding 
(Figure 3.8). However, when rhGH spiked in serum sample was injected to the very same 
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spot functionalized with rhGH antibody, signal enhancement was observed. In 
conclusion, the Nano-SPRi platform has demonstrated excellent specificity and    
selectivity for rhGH.  
 
 
Figure 3.8. Assessment of Nano-SPRi Selectivity to rhGH. The Nano-SPRi biosensor 
response after rhGH (black) and IGF-1 (red) are injected in spiked serum. 
	
	
III.3.7 Correlation Analysis Between ELISA and SPRi Results 
A correlation analysis was performed using the Pearson correlation coefficient to 
determine the correlation between the SPRi signal intensity and ELISA optical density 
values (Figure 3.9). A p-value < 0.01 was considered significant. As illustrated in this 
graph, there is a good correlation between the rhGH levels in spiked human serum 
measured by SPRi and ELISA. The r-value was 0.9263 for 9 different samples. 
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Figure 3.9. Pearson Correlation Analysis Between ELISA and Nano-SPRi. The plot 
correlates Nano-SPRi signal intensity (y-axis) with ELISA optical density (x-axis) 
values. (Pearson correlation coefficient n=9, r=0.9263, p=0.00000183). 
	
	
III.3.8 Kinetic Analysis of the Binding Event in ELISA and SPRi  
The equilibrium dissociation constant (KD) was determined using the graphpad 
software for ELISA. The calculated KD value was approximately 79 nM (Table 3.3). The 
on (Ka) and off (Kd) rates could not be determined by ELISA. However, using the data 
analysis software, the direct detection method resulted with KD value of 23 pM using the 
molecular mass of 22 kDa that corresponds to one rhGH molecule. The on and off rates 
were calculated to be 6.1 x107 M-1s-1 and 1.33x10-3 s-1, respectively. This inherently 
translates that 0.13 % of the rhGH and antibody complexes decay per second. As for the 
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amplified SPRi experiment, a stronger overall interaction was observed between 
NanoEnhancers and rhGH as the calculated binding affinity was determined to be 4.3 
pM. In addition, a stronger association rate was observed for NanoEnhancers and rhGH 
than capture antibody/rhGH, however the dissociation rate suggests that 0.26 % of 
NanoEnhancer/rhGH/Capture antibody decay per second.  
 
Table 3.3. Full Kinetic Data Analysis Including the Evaluation of the Affinity, On-
rate and Off-rate of the Antibody Responses Using Graphpad (ELISA) and Data 
Analysis (SPRi and Nano-SPRi) Software. The determination of the avidity using 
the molecular mass of 22 kDa that corresponds to one rhGH molecule was chosen. 
The limits of detection were determined for all three studies using excel. 
	
Method KD (Affinity) Ka  (on-rate) 
Kd  (off-
rate) 
LOD 
ELISA 79.45 x 10-9 M NA NA 1 ng/mL 
SPRi 23.2 x 10-12 M 
6.1 x 107 M-
1s-1  
1.33 x10-3 
s-1 
3.61 ng/mL 
Nano-SPRi 4.33 x 10-12 M 
7.54 x108 M-
1s-1  
2.62 x10-3 
s-1 
0.0092 
ng/mL 
 
 
III.4 Conclusions 
Irregular levels of hGH, a naturally occurring hormone, have been linked to 
numerous medical disorders that affect human growth and development. Moreover, 
exogenous administration of rhGH is commonly used by athletes, even though it is 
forbidden, as a doping agent to enhance their performance. Challenges in detecting rhGH 
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misuse result from the difficulty in distinguishing exogenous hGH from endogenous 
form. As such, the current approved technique for detecting exogenous hGH relies on 
measuring the ratio of the 22 kDa hGH isoform in relation to the 20 kDa isoform. Since 
the isoform test demands for the measurement of multiple hGH isoforms simultaneously 
within a short period of time in a wide range of concentrations, therefore, we considered 
the SPRi platform as a perfect match. In addition, endogenous hGH level fluctuate to a 
very low level (0.03 ng/mL) in the bloodstream therefore the detection system must be 
able to measure this range comfortably with high specificity. As a result, we also 
investigated in this study the potential of Nano-SPRi as a diagnostic tool for hGH and 
compared it directly with SPRi and the classical immunoassay ELISA.  
Based on results obtained from this study, the main advantage of the SPRi and 
Nano-SPRi method is that rhGH concentrations can be measured in a quicker manner in 
comparison to the more conventional method ELISA. A standard duration for measuring 
rhGH levels in one sample with the direct detection method was one hour whereas the 
Nano-SPRi required two hours due to the additional steps in the process. Overall, with 
SPRi and Nano-SPRi experiments, before the injection of a sample, a calibration step is 
highly recommended. In addition, the injection of a crude sample like human serum 
results in some non-specific interactions as a result it is imperative to inject a high salt 
wash buffer to only reveal specific interactions. It is also worth noting that a wash step is 
absolutely necessary after the introduction of blocking molecules to the sensor surface, to 
remove unbound molecules. As for ELISA time requirements are far greater (~16-18 h) 
for the analysis of one sample. A longer incubation time is needed as the sensitivity of the 
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assay is enhanced especially for this study, as the focus was to compare the lower limit of 
detection.  
The choice of surface chemistry will vary from one application to another and this 
could be realized as one of the limitation of the SPRi technique. In this study, a wide 
range and combination of chemical linkers and blocking molecules were assessed to 
achieve the right combination in order to observe optimal binding efficiency of rhGH to 
the sensor surface. For example, in this study, the combination of BSA and PEG served 
well in minimizing non-specific interactions. However, in a previous study [71], where 
the capture ligand was an aptamers, PEG alone served as the best blocking molecule. The 
variables that affect binding efficiency of analyte to ligand are also dependent on pH, 
buffer and temperature. Therefore, with any application, these variables need to be 
optimized. In addition, it is critical to determine the optimal spotting concentration of the 
ligand to the chip surface. A titration experiment with a range of concentrations of 
immobilized ligands is performed before initiating the study. As for ELISA, a crucial step 
in the procedure was to decant the wash buffer from wells by tapping the microplate as 
this ensured no residual liquid is leftover. Removing the buffer wash with pipette was not 
sufficient as any residual liquid interfered with the signal reading of the target sample.  
In reference to sensitivity, ELISA (1 ng/mL) is comparable to SPRi (3.61 ng/mL) 
but nano-SPRi (9.20 pg/mL) improves sensitivity by three orders of magnitude, thereby 
enabling measurements at the lower biological levels of rhGH 0.03 ng/mL. As we 
previously reported [55, 71], the signal enhancement imparted by the NanoEnhancers is 
attributed to a mass loading effect and the strong coupling that exists between NIR 
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fluorophores and propagating surface plasmons for gold film nanostructures. Even 
though, Nano-SPRi adds an extra step to the procedure, this level of sensitivity can widen 
the applications of SPRi technology in various outlets. 
 SPRi provides scientists a full kinetic profile (KD, Ka and Kd) of antibody/rhGH 
interaction whereas ELISA can report only affinity values. The coefficient of variation 
(CV) was below 10 % for SPRi (4.1 %) and ELISA (6.5 %), suggesting good 
reproducibility. The ELISA and SPRi affinity values are different because the capture 
antibodies immobilized on the sensor chip are different from antibodies immobilized in 
the ELISA 96-well plate. As for Nano-SPRi a higher CV value (20 %) was observed. 
There are several parameters that can contribute as a source of errors for CV 
determination. For example, with the Nano-SPRi experiment a much lower concentration 
of analyte is being measured, the addition of NanoEnhancers adds another step in the 
procedure and the experiment was performed manually. A very good correlation between 
Nano-SPRi and ELISA was achieved for the detection of rhGh in spiked human serum. 
Finally, ELISA can be a reliable technique however the method itself is time consuming 
which makes it difficult to use in situations requiring real time monitoring and 
multiplexing, as it is the case with hGH. In addition, a more attractive feature that was 
not investigated directly in this study that SPRi offers over ELISA is the ability to 
measure hundreds of interactions simultaneously in real time.  
In conclusion, this work presents Nano-SPRi as an ultrasensitive and accurate 
sensing platform for the detection of hGH biomarker in serum in comparison with 
conventional ELISA. Therefore in the next study, Nano-SPRi method will be assessed to 
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detect multiple biomarkers simultaneously in real time (multiplexing) at various 
concentrations in order to examine its potential as a viable clinical diagnostic tool. 
Furthermore, surface design will be improved to allow for a more reproducible 
immunosensor using an oriented method of antibody immobilization instead of direct 
covalent attachment. In addition, another hormone, progesterone, will be detected in the 
third work using Nano-SPRi. In this setup, the sensor surface is composed of x-aptamers 
immobilized on the sensor surface as the binding ligands specific for progesterone. This 
novel aptasensor is developed to offer the first label-free sensing assay capable of 
detecting progesterone in real-time and at very low concentrations (1 nM).  
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CHAPTER IV 
	
MULTIPLEX DETECTION OF ORGAN INJURY BIOMARKERS USING SPRI  
 
BASED NANO-IMMUNOSENSOR 
	
	
IV.1 Introduction 
Despite recent advances in targeted therapy and surgical care that have caused a 
drastic decrease in mortality rates, irreversible organ failure persists as the leading cause 
of high morbidity in critically ill patients [74, 75]. In most cases, the curative strategies 
fail to halt organ disease progression before reaching an irreversible stage due to a delay 
in the decision to begin treatment. The medical intervention decision often depends on 
clinical tests to observe for indicative biomarkers in bodily fluids. The development of 
such sensitive and non-invasive clinical assays not only will allow medical treatment at 
early stages; but also will enhance curative strategies, improve the quality of life and 
invoke better insight onto the mechanistic basis of organ injury.  
Currently many analytical techniques with varying sensitivity and specificity have 
been developed and employed to detect clinical biomarkers; however, they are very 
limited in predicting disease progression at early stages. Mass spectrometry-based tools 
for example 2D/MALDI-MS and LC-MS/MS suffer from low sensitivity and require 
intensive data analysis done by professionals [76]. Immunoassays on the other hand such 
as enzyme linked immunosorbent assay (ELISA) are labor intensive, require frequent  
calibration, and are incapable of acquiring data in a high-throughput manner [77]. As for 
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nucleic acid based assays not only require complex hardware setup but also suffer from 
interference in some matrix types [78, 79]. Finally, in most of these assays, the degree of 
accuracy highly depends on the expertise of the pathologist. Hence, there is a lack of 
diagnostic tools that could accurately detect a panel of clinical biomarkers at the earliest 
time point possible and provide immediate results in a simple use manner and this 
presents itself to be the major impediment to treating organ injuries. 
In the present work, an in vitro diagnostic optical assay based on surface plasmon 
resonance imaging (SPRi) is used to overcome the drawbacks of currently used tests to 
sensitively assess individual or multiple organ injury biomarkers at the same time. SPRi 
is a non-labeling and real time optical technique for the detection and analysis of 
biomolecular interactions at the surface of a high refractive index glass prism coated with 
a thin layer of metal. The sensing mechanism measures changes in refractive index up to 
~ 300 nm from the metal surface. The surface plasmons are sensitive to refractive index 
changes occurring in the vicinity of the metal layer; hence, serving as the basis of the 
detection of biomolecular interactions. 
Since the SPRi microarray platform allows for the quantitative detection of 
multiple interactions simultaneously better known as multiplexing, many studies have 
focused on this promising application to screen a variety of analytes in multiple matrices. 
For example, one group responded to the need of screening antimicrobial drug residues in 
milk due to their possible health risks by developing a competitive immunoassay for the 
simultaneous detection of seven drug residues down to ppb levels [80]. Others have 
extended multiplex sensing to low molecular weight protein biomarkers with clinical 
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significance in the body, such as ß2-microglobulin (MW=11.8 kDa) and cystatin C 
(MW=13.4 KDa) to reach nM limits of detection [81]. Multiple inflammatory cytokines 
(IL-1, IL-6, and TNF-α) were also detected in saline buffer and cell culture medium at 
ng/mL levels to better serve in understanding disease diagnosis and progression [82]. 
Moreover, the parallel detection of cancer biomarkers in buffer and in blood samples has 
attracted much interest in a number of studies leading to the construction of robust and 
low-fouling assays with good sensitivity to improve current diagnostic tests [83, 84]. 
Therefore, excellent potential has been demonstrated by the novel list of microarray 
biosensors developed; however, sensitivity and reproducibility are key features that still 
demand improvements to meet the needs for clinical diagnostic analysis. Developing 
novel immobilization techniques that avoid alterations to the functionalities of biological 
receptors and adopting signal enhancers to decrease the limit of detection of biomarkers 
represent the areas where improvement can be applied for enhanced reproducibility and 
performance.  
Hence, the work presented here introduces a dual microarray platform for the 
multiplex and ultrasensitive detection of two biomarkers, the High Mobility Group Box 1 
(HMGB-1) and Kidney Injury Molecule-1 (KIM-1) biomarkers, which have shown 
potential prognostic value in acute liver disease [85-87] and acute renal failure 
respectively [88]. This platform incorporates specific capture antibodies for both 
biomarkers on the surface and NanoEnhancers (NIR quantum dots)-labeled detection to 
enable the ultrasensitive detection of biomarkers at 5 pg/mL (200 fM) concentrations. 
From our previous work, enhancing the sensitivity of SPRi was achieved using 
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NanoEnhancers independent of the type of capture ligand or analyte and even 
environmental conditions [55, 89]. Moreover, we will further improve the sensitivity of 
the immunosensor by immobilizing antibodies in a well-oriented manner to increase the 
reproducibility as well as sensitivity of the analytical measurements. Ultimately, the early 
detection of these biomarkers could provide detailed information on the evolution of the 
disease and assist in refining patient care.  
IV.2 Methods 
IV.2.1 Materials and Chemicals 
Bare gold biochips were purchased from Horiba Scientific. Nanostrip was 
purchased from Cyantek (CA, USA). Protein A was purchased from protein mods (WI, 
USA). KIM1 and HMGB1 capture antibodies were purchased from abnova (Taipei, 
Taiwan). Biotinylated HMGB1 detection antibody was purchased from abnova and 
KIM1 detection antibody was also purchased from abnova and was functionalized with 
biotin using the biotinylation kit purchased from VWR (PA, USA). The fc fragment was 
purchased from EMD Millipore (MA, USA). Rabbit IgG polyclonal antibodies, 
polyethylene glycol (PEG2000), and bovine serum albumin (BSA) were purchased from 
Sigma Aldrich (PA, USA). Phosphate buffered saline (PBS) tablets and D (+)-Sucrose 
were purchased from fisher scientific (PA, USA). Streptavidin coated near infrared 
quantum dots (NIR-QDs) were purchased from life technologies (NY, USA).  
 IV.2.2. Sensor Surface Preparation 
The bare gold biochip was cleaned using a nanostrip solution (under sonication 
for 90 mins, 50˚C) and then rinsed thoroughly with deionized water, dried with a stream 
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of Nitrogen and placed in the UV/Ozone for 5 mins prior to surface functionalization. 
Protein A (5 g/mL) was immobilized on the surface of the biochip and incubated for 4 
hours at room temperature and a relative humidity of ~75%. Following this step, capture 
antibodies specific for KIM-1 (50 g/mL), HMGB-1 (50 g/mL) as well as Rabbit IgG 
antibodies (50 g/mL, negative control) were deposited on the surface (500 m spots) 
using a LabNext Microarrayer system. This spotting system prints the antibodies in an 
orderly and systematic manner on the sensor chip using a 500 m Teflon pin. It is 
important to note that both KIM-1 and HMGB-1 antibodies along with the negative were 
attached to the surface in the multi-target sensor surface design; however, only one type 
of antibody with the negative control was immobilized in the individual biomarker 
detection measurements to determine the limit of detection.  
The biochip was then allowed a 2-hour incubation time for efficient 
immobilization at room temperature and relative humidity of 75%. Prior to SPRi 
measurements, the functionalized surface was blocked inside the instrument using a 
combination of PEG2000 (2 mM) and BSA (1%) sequentially injected above the sensor 
surface.  
 IV.2.3. SPRi Measurements 
The analysis of biomolecular interactions of the different capture ligands with the 
corresponding biomarkers was performed in a Horiba SPRi-PlexII model (Horiba 
Scientific, France) designed particularly for multiplexing purposes. The biochip was 
loaded into the hexagonal flow cell (11 µL capacity) inside the instrument and a running 
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buffer (10 mM PBS, PH=7.4), controlled at a rate of 20 L/min by a continuous flow 
syringe pump (Harvard Apparatus PHD 2000 Infusion), was flown over the surface. 
Specific spots of each capture antibody (24 spots, 400 µm diameter each) were selected 
and defined using the SPRi view software. The sensing mechanism utilized a high 
stability LED incident light source that hits the glass prism coated with 5 nm Chromium 
adhesion layer and 50 nm gold, a detector that collects the resulting reflected light and a 
CCD camera that provides a real-time digital contrast image of the sensing surface. This 
image component reflects the biomolecular binding events happening at the metal 
surface; hence, confirming the changes in reflectivity in the SPRi response. Bright areas 
on the surface represent a binding event and dark spots are vice versa.   
Prior to kinetic monitoring, the surface was sequentially blocked by the injection 
of PEG2000 (2 mM) and BSA (1%) prepared in the running buffer. This is followed by a 
calibration procedure involving the injection of sucrose (3 mg/mL) above the surface to 
account for buffer changes in all ligand spots on the surface. The flow rate was then 
slowed down to 10 L/min and allowed to equilibrate prior to the interaction 
measurements. This is done to permit an increased interaction time between the 
biomarker and the capture antibody until the detection and amplification probe are 
introduced to the surface.  
The kinetics of the biomolecular interactions was monitored through the 
sequential injection of the biomarkers, fc fragment, biotinylated detection antibodies and 
finally the NIR-QDs for signal amplification.  Each injected sample was prepared in the 
running buffer at room temperature. The fc fragment was introduced after the biomarkers 
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to avoid any possible steric hindrance blocking the antibody-binding site from reacting 
with the biomarker of interest. The introduction of biotinylated detection antibodies 
served to bind to the analyte on one hand and to the streptavidin coated NIR QDs through 
the strong biotin/avidin non-covalent interaction on the other hand.  
The SPRi response reported is the average response of 4 spots of each capture antibody 
on the surface with the non-specific (negative control) signal subtracted.  
IV.3 Results 
IV.3.1 Biosensor Surface Optimization  
The overall performance of the SPRi biosensor highly depends on the quality of 
the surface functionalization and the proper anchoring of the biorecognition probes onto 
the metal surface. Most gold surfaces are functionalized by alkanethiol organic 
compounds as the primary building blocks onto which the biological ligands are 
covalently bound. For example, the immobilization of antibodies in immunoassays can be 
performed by the amine coupling of lysine residues in antibodies to the surface linked 
carboxylic acid groups through an EDC/NHS intermediate activation step. This surface 
chemistry has been widely used and successful in many previous works [90-92]; 
however, we found this strategy to be characterized by inconsistency in surface 
uniformity from one experiment to the other as shown (Figure 4.1). Therefore, we chose 
to design the capture array by immobilizing the KIM-1 and HMGB-1 monoclonal capture 
antibodies onto a protein A coated surface to avoid structural alterations to the antibodies, 
ensure proper orientation of the antibody and uniform coverage on the surface [93]. We 
found that coating the surface with protein A (5 µg/mL) solution for 4 hours enabled a 
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homogeneous coverage and active binding of the capture antibodies spotted on the 
surface, which enhanced the sensitivity and reproducibility of the SPRi response.   
 
 
 
Figure 4.1. Comparative Biosensor Behavior in Response to HMGB-1 (4 µg/mL) in 
Buffer. Both experiments A and B were carried out under the same conditions and 
prepared using the alkanethiol/EDC/NHS surface onto which the HMGB-1 
monoclonal capture antibodies were covalently bound (amine coupling). Experiment 
(a) resulted in a low specificity signal of ΔR = 3%; while experiment (b) gave a lower 
and inconsistent response of ΔR = 1.5%. 
	
	
IV.3.2 Minimizing Non-Specific Interaction  
A well-designed immunoassay sensor not only relies on the proper 
immobilization of the biological ligands but also on the suppression of non-specific 
adsorption of analyte on the metal surface. And the challenge lies in choosing a blocking 
a b 
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agent of suitable dimensions and properties that can minimize the potential of non-
specific signal but at the same time allow accessibility to the binding site of the 
bioreceptor. In this study we found that the sequential blocking using 2 mM polyethylene 
glycol (PEG2000) and 1% bovine serum albumin (BSA) provided optimal coverage of 
the surface against non-specific adsorption of analyte. The concentrations used were 
critical as increasing the concentration of PEG2000 from 0.1 mM to 2 mM while keeping 
the BSA concentration at 1% as well blocking the surface with proper sequence, 
enhanced the signal significantly from (1.7% ΔR, ±0.18) to (3.45 % ΔR, ±0.08), as 
shown in Figure 4.2. In addition, the protein A coated surface was further blocked by fc 
fragments (0.5 µg/mL) after injection of biomarker in order to occupy the free protein A 
regions not bound to the immobilized antibodies. Hence, with the combination of 
multiple agents, we were able to reach a negligible non-specific binding signal allowing 
our platform to perform successfully in the multistep sensing mechanism.  
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Figure 4.2. Comparative SPRi Sensorgrams to HMGB-1 Binding to Two Surfaces 
Under Different Blocking Conditions. Above figure represents the binding kinetics 
of HMGB-1 (50 ng/mL) to two surfaces functionalized with HMGB-1 capture 
antibodies (50 µg/mL) and blocked under two conditions. The first surface was 
blocked using a combination of 0.1 mM PEG2000 and 1% BSA resulting in a signal 
of 1.7% ΔR, ±0.18 (red solid line).  While the second surface was blocked using a 
combination of 2 mM PEG2000 and 1% BSA and the binding of HMGB-1 resulted 
in a signal of 3.45 % ΔR, ±0.08 (black dotted line). 
	
	
IV.3.3 Singleplex Measurements of KIM-1 and HMGB-1  
A sandwich assay was used to detect KIM-1 and HMGB-1 separately at low 
concentrations in buffer. The capture array was first coated with protein A (5 µg/mL, 4 
hours) and then monoclonal KIM-1 and HMGB-1 antibodies and rabbit monoclonal IgG 
antibodies (negative control) were directly attached to the surface at 50 g/mL spotting 
concentration. The functionalized biosensing surface was then blocked using a 
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combination of BSA (1%) and PEG2000 (2 mM) inside the instrument. The detection of 
biomarkers was accomplished in a three-step process.  
At first, the biomarker was injected and followed by sequential injection of the fc 
fragment to block the unoccupied protein A bound to the sensing surface. Secondly, 
specific biotinylated KIM-1 detection antibodies were injected to bind to the captured 
analyte. Finally, the signal amplification was accomplished with a non-interfering 
streptavidin coated NIR quantum dot (NanoEnhancers).  The introduction of NIR 
quantum dots in the amplification process is known to lead to signal amplification due to 
the mass loading effect of the nanoparticles and possible emission coupling with the 
oscillating surface plasmons on the metallic surface [55].  
A concentration range (0.005, 0.05, 10, and 50 ng/mL) of HMGB-1 biomarker in 
phosphate buffer was detected and the specific SPRi responses obtained are presented in 
(Figure 4.3). Secondly, a concentration range (0.005, 0.05, 0.5, and 50 ng/mL) of KIM-1 
biomarker was tested and the results of the SPRi response are shown in (Figure 4.4). 
From these plots we were able to calculate the limit of detection for both biomarkers to 
be 5 pg/mL.  
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Figure 4.3. A Concentration Profile of Nanoenhanced SPRi Signal in Response to 
HMGB-1 in Buffer. SPRi response (%∆ Reflectivity) represents the NanoEnhanced 
response upon the binding of NanoEnhancers to the various concentrations of 
HMGB-1 biomarker (ng/mL) in phosphate buffer. The % change in reflectivity 
reported takes into account the IgG negative control signal, which is subtracted 
from the overall signal. 
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Figure 4.4. A Concentration Profile of Nanoenhanced SPRi Signal in Response to 
KIM-1 in Buffer. SPRi response (%∆ Reflectivity) represents the NanoEnhanced 
response upon the binding of NanoEnhancers to the various concentrations of KIM-
1 biomarker (ng/mL) in phosphate buffer. The % change in reflectivity reported 
takes into account the IgG negative control signal, which is subtracted from the 
overall signal. 
	
	
IV.3.3 Multiplex Measurements of Both KIM-1 and HMGB-1  
To further investigate the multi-target potential of this biosensing platform, both 
KIM-1 and HMGB-1 antibodies along with the negative rabbit IgG control were spotted 
on the same surface at 50 g/mL concentrations. The multiplex detection involved a 
three-step sandwich assay process very similar to the individual biomarker detection 
previously presented. The first step involved the injection of both biomarkers in buffer 
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followed by injection of fc fragment (0.5 µg/mL) to further block the unoccupied protein 
A regions. The second step introduced the biotinylated KIM-1 detection antibody and 
finally the NIR streptavidin-coated QDs were injected as the amplification probes (Figure 
4.5).  
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Figure 4.5. The Step-Wise Experimental Approach in the Design of Sandwich 
Assay. The setup demonstrates the sequential steps performed to design the 
immunosensor surface as well as to carry out the multiplex measurements of both 
KIM-1 and HMGB-1 biomarkers. Firstly, a clean surface is coated with protein A, 
followed by the immobilization of monoclonal antibodies, and then the surface is 
blocked with a combination of PEG2000 and BSA. The multiplex measurements are 
carried out by the sequential injection of biomarker, fc, biotinylated secondary 
antibody and finally NanoEnhancers to amplify the signal. 
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The results of the multiplex sandwich-amplification assay that detects HMGB-1 
(0.5 ng/mL), KIM-1 (50 ng/mL) and IL-6 negative control (50 ng/mL) are presented in 
Figure 4.6. The SPRi response is highest for the KIM-1 biomarker (~ 2% ΔR, ±0.64), and 
lower for the HMGB-1 biomarker (~0.9 % ΔR, ±0.12), with a negligible signal for the 
IL-6 negative control. 
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Figure 4.6. Multiplex SPRi Sensorgram of KIM-1, HMGB-1 and IL-6 Control.  The 
sensorgram represents the Nanoenhanced SPRi response  (%∆ Reflectivity) versus 
time (s) of 50 ng/mL KIM-1 biomarker (dotted red line), 0.5 ng/mL) HMGB-1 
biomarker (solid black line), and 50 ng/mL IL-6 control (dashed blue line) measured 
in phosphate buffer. 
	
 
IV.4 Conclusions 
We adopted a non-covalent attachment setup to immobilize the capture antibodies 
onto the sensing surface in order to avoid inconsistent results and enhance the 
reproducibility of the assay [93]. The inconsistency resulting from the chemical 
attachment of antibodies could perhaps be caused by the disordered orientation of the 
capture probes on the surface, which in turn could lead to loss of biological activity and 
hindrance in the analyte accessibility onto the binding site [94]. Protein A was bound to 
the sensing surface as the primary building block through the thiol-gold bond onto which 
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the antibodies will be spotted. Protein A is mainly used in antibody-purification columns 
as it binds to the fragment crystallizable (fc) region of the antibody leaving the antibody-
antigen binding site (Fab) accessible to bind to the biomolecule. An optimal density of 
protein A (5 µg/mL) and a spotting concentration of the capture antibodies (50 µg/mL) 
were utilized in the platform to ensure exposure of the binding site of the antibody and a 
sterically favored distance between the assembled antibodies. As a result, the sensing 
capability of the assay was enhanced and showed good reproducibility.   
Moreover, functionalizing the surface with non-fouling materials took many 
attempts prior to finding the proper combination as well as concentration. It is important 
to note that this surface design allows more exposure to the bare gold metal surface than 
surfaces covered with alkanethiol groups in the layer below the antibodies. Therefore, 
blocking with PEG2000 chains allowed (2 mM) coverage of the areas between the 
spotted antibodies through the thiol-gold bond as well as the rest of the sensor chip. 
Additionally, blocking with BSA (1 %) was performed to offer extra protection as a 
coating layer to the protein A regions that were not occupied with antibodies. Since this 
surface setup is used for the first time in multiplex sandwich-amplification assay, a 
further non-specific adsorption challenge arose from the possible binding of the 
biotinylated complementary detection antibodies to the protein A. Therefore, to avoid 
that problem, fc was injected to occupy the remaining unoccupied protein A sites. 
Furthermore, the injection occurred after the injection of the analyte in order to prevent 
any steric hindrance that fc might cause to the binding site of the capture antibodies.  
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Finally, with all the surface development steps accomplished, singleplex detection 
for both HMGB-1 (~29 kDa) and KIM-1 (30 kDa) was performed in a sandwich-
amplification assay achieving a limit of detection of 5 pg/mL (200 fM) for both 
biomarkers. This high level of sensitivity was accomplished by the addition of the 
NanoEnhancers resulting in superior sensitivity and limits of detection compared to 
reported values from currently exploited detection tools as it is highly important to detect 
these biomarkers at early stages [95]. For example, a LOD of 10 ng/mL in serum for 
HMGB-1 was achieved utilizing a combination of aptamer nanotechnology and 
electrophoresis [96], and a LOD of 2 ng/mL in an ELISA assay performed to selectively 
detect HMGB-1 in serum [97]. On the other hand, KIM-1 was detected using an 
immunochromatographic assay at concentrations higher than 800 pg/mL [98]. A further 
contribution to obtain more insight on disease detection and progression is accomplished 
by the multiplex sandwich-amplification assay that detects HMGB-1 (0.5 ng/mL) and 
KIM-1 (50 ng/mL) simultaneously to yield a higher signal for the KIM-1 biomarker (~ 
2% ΔR), a lower signal corresponding to the HMGB-1 biomarker (~0.9 % ΔR) as 
expected, and a negligible signal for the IL-6 negative control. From these results, we can 
conclude that the platform demonstrates specificity and selectivity. 
The enhancement in SPRi signal caused by the addition of the NanoEnhancers to 
the sensing surface could perhaps be caused by multiple reasons. The NanoEnhancers are 
heavy metal nanoparticles that result in a high mass loading effect responsible for the 
increased SPRi response. In addition, the NIR quantum dots possess unique quantum 
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properties, which could possibly allow energy coupling with the gold metal layer on the 
surface as reported in one previous study [55]. 
In this article, we propose a real-time, label-free, and multiplex nanoenhanced 
SPRi platform to quantitatively assess two biomarkers, kidney injury molecule (KIM-1) 
and high mobility group box-1 (HMGB-1) simultaneously in buffer. Our work involves 
three major contributions in the design of the immunosensor: (1) we applied site-specific 
immobilization of antibodies to the solid surface that avoids loss of biological activity 
obtained with covalent attachment; (2) we constructed a well-blocked sensor surface that 
experiences minimal non-specific adsorption for singleplex measurements of each 
biomarker in buffer; and (3) we adopted a sandwich assay that implements functionalized 
quantum dots (NanoEnhancers) as signal enhancers to achieve a sensitivity level of 5 
pg/mL for KIM-1 and HMGB-1 in buffer. We foresee great potential and success in 
extending this multiplex and ultra-sensitive platform to assess a variety of other emerging 
clinical biomarkers at low concentrations and in complex matrices. 
In future work, the proposed platform can be further investigated for the analysis 
of a vast number of different biomarkers simultaneously and in a variety of complex 
matrices. Furthermore, potential adjustments to the platform can advance the multiplex 
effectiveness of the technique to not only assess biological molecules and organ injury 
biomarkers; but also environmental toxins, microbes, drugs and many more. Therefore, 
we anticipate great contribution from the practical capabilities of this platform to 
medical, pharmaceutical and environmental research.  
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CHAPTER V 
	
ULTRASENSITIVE DETECTION OF PROGESTERONE USING A NANO-SPRI  
 
BASED APTASENSOR 
	
	
V.1 Introduction 
Steroid hormones are a family of small hydrophobic analytes derived from 
cholesterol that have been the targets in many clinical assays being developed for the 
detection of steroid hormones in a variety of bodily fluids and at very low concentrations 
[99]. Progesterone, a steroid hormone composed of four cyclic hydrocarbons containing 
oxygenated functional groups such as ketones, serves as an indicator of early pregnancy, 
and participates in controlling hormonal levels throughout the reproductive cycle. Its 
sensitive detection in diverse matrices can assist in fertility investigations [100, 101]. 
Progesterone normally ranges in level from less than 1 ng/ml serum in the pre-ovulation 
phase of the menstrual cycle up to 20 ng/ml in mid cycle, and to 300+ ng/ml in 
pregnancy. Immunoassays such as ELISA [102], electrophoresis-chemiluminescence 
detection [103], and non-competitive idiometric or fluoroimmunoassays [104], have been 
the most  widely used methods for the detection of progesterone in different matrices. 
These tests require very carefully operated procedures, skilled experts to carry out the 
analysis, and labeled probes to detect the steroid. In addition, the major drawback of these 
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clinical tests is the high levels of interference arising from the structural similarities of the 
different hormones [99]. SPRi biosensor technology offers a reliable analytical tool to 
generate accurate and label-free signal detection of progesterone, real-time data acquiring, 
and semi-automated operation. This potential platform has been utilized to measure 
progesterone by employing well-developed immunoassays that utilize monoclonal 
antibodies as the binding ligands and sensitive surfaces. For example, an inhibition 
immunoassay procedure was adapted for measuring progesterone levels in cow’s milk 
and human saliva to achieve a limit of detection of 3.5 ng/mL [105] and by further 
varying a number of parameters the same group was able to enhance the sensitivity down 
to 0.4-0.6 ng/mL in milk and 35-60 pg/mL in HBS-EP buffer [101]. Another study 
evaluated progesterone conjugated to different length ovalbumin linkers to determine the 
effect of these linkers on the anti-progesterone binding activity to achieve a sensitivity 
range from 0.1-50 ng/mL [106]. Signal enhancement probes such as gold nanoparticles 
were also investigated for their potential to detect progesterone conjugated to ovalbumin 
to lower the limit of detection to 4.9 ng/L in an inhibition immunoassay [107]. A similar 
platform was developed by Mitchell et al., which consisted of immobilizing progesterone 
on the surface with oligoethylene glycol linkers and gold-streptavidin labels to lower the 
detection limit to 8.6 pg/mL [108]. As concluded from the studies reported, the SPR 
systems have been capable of providing a successful means of detection for progesterone. 
Nevertheless, the use of monoclonal antibodies as the capture ligands continues to pose 
an obstacle for sensitive, rapid and reproducible detection of progesterone.  Most of the 
studies presented utilized an inhibition immunoassay, which required additional 
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preparation and use of larger amounts of antibodies prior to analysis; whereas a direct 
detection platform eliminates this additional step. Moreover, most of the detection 
strategies relied on modifying progesterone with linkers for immobilization to the sensor 
surface due to the small size of progesterone and its hydrophobic properties. This 
conjugation strategy can possibly alter the three-dimensional structure of the hormone and 
cause steric hindrance; hence, decreasing the sensitivity and reproducibility of the 
analytical measurements.  
In this work, we introduce the use of progesterone x-aptamers as an alternative to 
monoclonal antibodies used in immunoassays for the ultrasensitive detection of 
progesterone in buffer. The setup that we adopt eliminates the need to covalently 
immobilize progesterone to the solid metal surface; hence, preserving the activity and 
steric accessibility of progesterone.   
We also aimed to enhance the small molecule sensing by using a SPRi 
NanoEnhanced sandwich assay to allow for ultrasensitive detection of progesterone. 
Aptamers are short single-stranded oligonucleotide sequences, which mimic antibody 
binding to an analyte such as progesterone but with an enhanced sensitivity, specificity, 
and affinity. [109]. Furthermore, the use of aptamers may circumvent the problems of 
steric hindrance that occur between small molecules and large antibodies and which can 
decrease the sensitivity of the detection platform [110-112].   
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V.2 Methods 
V.2.1 Chemicals and Materials 
 Bare gold chips were purchased from Horiba Scientific (France). Nanostrip was 
purchased from Cyantek (CA, USA). 11-mercaptoundecanoic acid, N-
Hydroxysuccinimide, Poly (ethylene glycol) methyl ether thiol (Mw=800) and Poly 
(ethylene glycol) methyl ether thiol (Mw=2000), extravidin, glycerol, ß-estradiol and 
acetonitrile were all purchased from Sigma Aldrich (PA, USA). 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide Hydrochloride was purchased from TCI 
America (PA, USA). Phosphate Buffered Saline, sodium chloride, and bovine Albumin 
Serum were purchased from Fisher Scientific (PA, USA). Progesterone was purchased 
from Cayman Chemical Company (MI, USA). Progesterone x-aptamers were selected 
using the AM Biotechnologies X-Aptamer kit and were synthesized by AM Biotech. 
Biotin-labeled interleukin 6 (IL-6) aptamers were purchased from base pair 
biotechnologies (TX, USA).  Near-infrared streptavidin-coated quantum dots were 
purchased from life technologies (CA, USA).  
V.2.2 X-aptamer Selection 
A library of X-aptamers, bound to synthetic micro beads, was provided by AM 
Biotech. Aptamer selection was carried out according to the protocol provided by AM 
Biotech. In addition to the negative selection suggested in the protocol (removal from the 
library of the aptamers that bind to streptavidin coated magnetic beads), a second negative 
selection was carried out to remove aptamers that bind to biotin. Streptavidin coated 
magnetic beads were mixed with the aptamer library, incubated for an hour and then were 
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removed (along with bound aptamers) using a magnetic stand. The remaining library was 
incubated with 100µM biotin for an hour and the biotin along with bound aptamers was 
pulled down through binding to streptavidin-coated beads. From the remainder of the 
aptamers in the library, primary selection of aptamers specifically binding to progesterone 
was performed by incubation of the library with biotinylated progesterone, followed by 
harvesting of the biotinylated progesterone along with bound aptamers using streptavidin 
coated magnetic beads. These harvested aptamers were cleaved from the synthetic micro 
beads using 1N NaOH. This pool of selected aptamers was divided into three aliquots. 
One aliquot was incubated with streptavidin coated magnetic particles. Aptamers bound 
to these beads were pulled down along with the magnetic particles. This fraction (fraction 
#1) represents aptamers that bind to streptavidin and magnetic beads.  Second aliquot was 
incubated with biotinylated progesterone. The bound aptamers were pulled down along 
with biotinylated progesterone through binding to streptavidin-coated beads. This is the 
fraction containing progesterone-binding aptamers (fraction #2). The third fraction was 
used as a representative pool of all aptamers selected in the primary selection. All three 
fractions were PCR amplified with specific reverse primer for each fraction. The PCR 
products were combined and used as template for next generation sequencing. From the 
sequences identified, those that were enriched in the fraction#2 were chosen as the 
sequences specific to progesterone binding aptamers.  Finally, AM Biotech synthesized 
the 9 x-aptamers selected using the kit.  
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V.2.3 Sensor Chip Functionalization 
 A bare gold sensor chip was cleaned under sonication using a nanostrip solution 
(50 °C, 90 mins) followed by thorough rinsing with ultrapure water. Then the sensor chip 
was placed in the UV/Ozone for 10 mins prior to surface functionalization. The first 
functionalization step with a layer of 11-MUA (34 mM in pure ethanol) was facilitated by 
microwave irradiation using a CEM discover microwave (50W, 50°C, 5 mins). The 
carboxyl groups of 11-MUA were activated by EDC first (65 mM in ultrapure water) in 
the microwave (50W, 50°C, 5 mins) and this was followed by reacting the surface with 
NHS (40 mM in ultrapure water) under the same conditions. Finally, PEG800 (1.25 mM 
in ultrapure water) is reacted with the sensor chip under the same microwave conditions. 
It is important to note that the sensor chip was washed thoroughly with ultrapure water 
between each functionalization step to ensure removal of unreacted chemicals. The chip 
was then dried with a stream of nitrogen and allowed to react with extravidin (0.2 mg/mL, 
10 mM PBS) at room temperature and a relative humidity of 75% for 1 hour. After this 
step, the avidin chip was prepared for the ligand immobilization step by a thorough rinse 
with ultrapure water and dried with a stream of nitrogen.  
V.2.4 Ligand Immobilization 
 The avidin sensor chip was spotted with the biotin-labeled library of progesterone 
x-aptamers and negative interleukin 6 aptamer. In the direct detection-sensing assay, the 
spotting concentration of both positive progesterone and the negative control IL-6 
aptamers was 100 µM and prepared in a phosphate spotting buffer (10mM PBS, 10% 
glycerol, PH=7.4) solution. In the sandwich amplification-sensing assay, the optimal 
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spotting concentration of both positive progesterone and negative control IL-6 aptamers 
was 5 µM and prepared in phosphate spotting buffer (10mM PBS, 10% glycerol, 
PH=7.4). The spotting was performed using LabNext compact Microarrayer and 300 µm 
teflon spotting pin. The biotin-labeled x-aptamers were allowed to react with the avidin 
surface at room temperature and a relative humidity of 75% for 2 hours. 
V.2.5 NanoEnhanced Binding Assay 
 The sensor surface was inserted into the SPRi instrument for assay analysis and a 
phosphate buffer (10 mM PBS, 4% Acetonitrile, PH=7.4) buffer was degassed and 
allowed to flow above the surface at room temperature and a flow rate of 5 µL/min. 
Further blocking of the sensing surface was performed inside the instrument by 
sequentially injecting a BSA solution (1%) followed by a PEG2000 solution (1 mM) and 
the non-bound molecules were washed properly from the surface between steps. A 
calibration step using a solution of sucrose (3 mg/mL, 10 mM PBS PH=7.4, 4% 
Acetonitrile) was then performed and that precedes the injection of the analyte. The 
samples injected were diluted in the running buffer and loaded to a 150 µL injection loop. 
In the direct detection-sensing assay, a solution of progesterone prepared in a 10 mM PBS 
and 4% acetonitrile solution was injected and the kinetics of the binding event were 
monitored. And in the sandwich amplification-sensing assay, the primary injection 
consisted of a specific concentration of progesterone sample followed 5 minutes after by 
the second injection consisting of a progesterone detection aptamer (x-aptamer #4) 
conjugated to the quantum dots. The signal amplification sample consisting of the 
detection aptamer (20 nM) was allowed to incubate with the streptavidin conjugated 
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quantum dots (10 nM) for 30 mins prior to injection above the sensing surface. And the 
kinetics of both steps was monitored in real-time. Finally, the SPRi sensorgrams were 
analyzed and the final plots were prepared using the ScrubberGen horiba software.  
V.3 Results 
V.3.1 Screening of Developed X-aptamers 
The biosensing assay was designed to achieve high specificity and selectivity for 
the detection of low progesterone titers down to 0.315 ng/mL levels. Specific aptamers 
were selected and employed as the surface ligands. Taking advantage of the strong bond 
between biotin and avidin, the aptamers were tagged with a biotin molecule; an avidin 
surface was employed for the direct attachment of the capture aptamer ligands to the 
sensing surface in a well-oriented manner. PEG800 was microwaved on the surface prior 
to the ligand immobilization since microwave irradiation of PEG-SH has been shown by a 
previous study to improve the effectiveness of the blocking process resulting in an 
enhanced SPRi response [89]. BSA (1%) and PEG2000 (1 mM) were further added to the 
surface inside the instrument to further block the sensing platform from non-specific 
adsorption of analyte. Long chain thiolated PEG offers the hydrophilic behavior that 
repels analyte molecules from binding non-specifically to the surface. The aptamers 
developed were screened for the detection of progesterone in the buffer (4% Acetonitrile, 
10 mM PBS) used to solubilize progesterone. Progesterone is highly hydrophobic; hence, 
acetonitrile was utilized to solubilize the steroid and enable its detection in a water-based 
buffer (10 mM PBS). The performance of each aptamer is presented in Fig. 5.1 in which 
the 9 aptamers evoked different SPRi signals after the injection of 50 µg/mL (150 µM) of 
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progesterone. As shown, x-aptamers 3, 5 and 4 resulted in the highest SPRi response 
(%ΔR=0.4 ± 0.01) upon the interaction with progesterone (150 µM); meanwhile, other x-
aptamers experienced a lower binding response especially x-aptamer 1 which showed 
similar SPRi signal to the IL-6 negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 73
 
Figure 5.1. Screening of All X-aptamers Using SPRi-based Direct Sensing. The SPRi 
sensorgrams of the interaction between progesterone (150 µM) and the 9 x-
Aptamers developed and the negative IL-6 control aptamer spotted at 100 µM 
concentrations. 
	
	
V.3.2 Direct Detection Assay Measurements 
With the biosensing assay we were able to select several high binding activity 
aptamers from the library of aptamers developed that detected progesterone at a 
concentration of 49 µg/mL (150 µM). The next step was to test a range of concentrations 
(15.75, 31.5, 63, and 126 µg/mL) of progesterone and monitor the SPRi response of the 
binding to one of the top aptamers (Aptamer #5), which produced the largest SPRi 
response (%ΔR) upon interaction with progesterone. Aptamer 5 was spotted on the 
surface (N= 6 spots) along with the IL-6 aptamer (N=6 spots) as a negative control; the 
kinetic analysis was performed. A linear correlation was obtained by increasing the 
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concentration of progesterone injected to the functionalized surface and the results are 
presented in Fig. 5.2. As it can be shown, the limit of detection was concluded to be 15.75 
µg/mL (50 µM) resulting in a response of  %ΔR=0.07 ± 0.01 for the direct biosensing 
assay. 
 
 
Figure 5.2. A Direct Detection Concentration Profile of SPRi Response of 
Progesterone in Buffer. The SPRi signal is obtained from the interaction of x-
aptamer #5 with progesterone in buffer at a concentration range (50-400 µM). 
	
	
V.3.3 Specificity Assay Measurements 
Aptamers are well known for their enhanced selectivity and specificity as minor 
structural differences between biomolecules can be distinguished through the recognition 
process [113]. Taking this potential property into account, we examined the specificity of 
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the positive aptamer (x-aptamer 5) by testing its detection against a closely related 
steroid, ß-Estradiol (63 µg/mL) that coexists with progesterone in blood serum during the 
mid-menstrual cycle.  The positive aptamer was chosen for further analysis due to its high 
binding SPRi signal shown in Fig. 2. The specificity assay was performed under the same 
conditions as the direct detection and utilized x-aptamer #5 with a solution containing ß-
Estradiol (63  µg/mL). As presented in Fig. 5.3, x-aptamer 5 showed significant 
specificity for only progesterone (%ΔR=0.40 ± 0.10) and showed negligible binding to ß-
Estradiol. 
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Figure 5.3. A Specificity Assay Comparing the SPRi Response of Positive X-
Aptamer 5 to Progesterone and ß-estradiol. SPRi sensorgrams of the response 
obtained from the interaction of aptamer #5 with progesterone (purple dotted line) 
and ß-estradiol (red solid line). Aptamer #5 demonstrated high-specificity as the 
SPRi signal obtained from the interaction with progesterone (63 µg/mL) is 
%ΔR=0.40 ± 0.10 compared to a negligible signal after exposure to ß-estradiol (63 
µg/mL). 
	
	
V.3.4 Sandwich-Amplification Assay 
 On the diagnostic front, SPRi assays could have tremendous impact if the 
capability to perform small molecule sensing at ultra-low concentrations is successfully 
achieved. As previously mentioned, small molecule sensing is still in its early stage of 
development because of the problem posed by low molecular weight. In this work, we 
employed nanoenhancers (NIR quantum dots) as special signal amplification probes to 
generate a detectable signal at very low concentrations of progesterone. The sandwich 
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assay was carried out with a three-step procedure. First, progesterone was injected 
followed by a detection aptamer (x-aptamer #4). X-aptamer 4 was tested as a detection 
aptamer due to its high binding as shown in the screening assay (Figure 5.1). Finally the 
nanoenhancers were added to produce the SPRi signal enhancement.  
A range of concentrations was examined in this setup to determine the lowest detection 
limit and thus, evaluate the sensitivity of the biosensing assay. The limit of detection was 
determined to be 0.315 ng/mL (1 nM).  The concentration profile of the tested 
concentrations of progesterone is represented in Figure 5.4.  
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Figure 5.4. A Sandwich-Amplification Assay Concentration Profile of Progesterone 
in Buffer. The SPRi response (%Δ Reflectivity) represents the interaction of 
nanoenhancers with the various amount of progesterone (0.005-10 µM) upon 
binding to x-aptamer #5. 
	
	
V.4 Conclusions  
We developed specific x-aptamers for progesterone using an X-Aptamer kit 
because this approach offers an advantage over conventional aptamers as well as 
monoclonal antibodies in the selective and ultrasensitive detection of progesterone. X-
aptamers are small single stranded DNA molecules that contain nucleotides with amino 
acid functional groups and other small molecules attached. These chemical modifications 
confer vast chemical diversity to the X-aptamers, allowing for increased specificity when 
binding to targets. This chemical diversity is made possible by the micro bead based and 
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non-PCR dependent selection process. In small molecule sensing, the accurate 
identification and detection of analyte necessitates highly sensitive capture ligands 
capable of efficiently binding to the analyte in solution in order to maximize the platform 
signal. Moreover, it requires that the capture ligands can discriminate between these 
structurally similar biomolecules that are present in the same complex samples. 
Therefore, introducing progesterone x-aptamers in combination with the Nanoenhanced 
biosensing capabilities of SPRi offer many advantages over currently used SPR-based and 
non-SPR based immunosensing assays.  
A validation of the binding capability of the x-aptamers was performed using the 
SPRi based assay. The screening of all x-aptamers was performed and x-aptamers (3, 4 
&5) showed the highest SPRi response (%Δ Reflectivity) results. The SPRi response 
reflects the binding activity occurring on the surface; hence, the higher the response the 
higher the binding occurring between the analyte and immobilized ligand. Hence, x-
aptamer #5 was chosen for the direct detection as well as the sandwich-amplification 
sensing assay.  
This work describes the first SPRi setup to our knowledge to detect progesterone 
in a mobile phase through the interaction with specific aptamer ligands bound to the 
sensor surface. Meanwhile, other SPR-based studies achieved the measurement in an 
inhibition assay in which progesterone was covalently bound to the metal surface and 
mobile antibodies were flown over the surface [114, 115]. The presented sensor surface 
design consisted of immobilizing the progesterone x-aptamers on the surface.  These 
progesterone aptamers were functionalized with a biotin reporter molecule at the 5’ end of 
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the oligonucleotide since this would allow the aptamers to be immobilized on the sensing 
surface. The implemented modification in this assay offers the advantage of carrying out 
direct measurements of progesterone. It also eliminates any alterations to the structure of 
progesterone resulting from modifications required to attach the steroid to the sensor 
surface. Furthermore, the mobile phase was optimized to allow complete solubilizing of 
progesterone, which is inherently insoluble in phosphate buffer.  We accomplished that 
step by using a mixture of acetonitrile (4%) and phosphate buffer (10 mM) as the 
preparation buffer of samples and running buffer.    
The use of amplification probes was designated to reach lower limits of detection 
and it significantly improved the performance of the biosensing assay. A detection limit 
of 0.315 ng/mL (1 nM) may be deduced from the range of low concentrations tested. The 
NanoEnhancers responsible for the higher sensitivity in the platform are made of heavy 
metal nanoparticles (quantum dots) that result in a high SPRi response once added to the 
bound detection probes. Moreover, the NanoEnhancers could possibly display an energy 
coupling phenomenon with the oscillating surface plasmons on the metal surface as 
proposed by Malic et al. [55]. Therefore, both the mass loading effect and the energy-
coupling phenomenon could be responsible for the enhancing effect the NanoEnhancers 
are demonstrating on the SPRi signal.  
Label-free small molecule biosensing is a key area in the development of 
advanced diagnostic tools and analysis assays that can shed light on numerous 
biochemical processes. In this study, we developed a biosensing surface capable of 
performing analysis in a label-free and real time manner while demonstrating the ability 
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to ultra sensitively and selectively distinguish between similarly structured hormones. 
And we anticipate that further investigation of the platform design can extend the 
diagnostic application to detect a variety of different steroids in complex matrices such as 
serum and saliva. Moreover, steroids can be detected simultaneously by employing a 
multiplex assembled sensor surface immobilized with highly specific x-aptamers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
	 82
CHAPTER VI 
	
CONCLUSION AND FUTURE PERSPECTIVES 
	
	
As a conclusion, ultrasensitive and selective measurement of different biomarkers 
was accomplished using a SPRi assay in combination with signal enhancers. The 
successful detection of hGH in serum at ultra-low concentrations using a monoclonal 
immunoassay has led to the development of a multiplex assay that assess disease 
biomarkers. The multi-target analysis required major improvements to the sensor design 
by altering the immobilization strategy of antibody ligands to the surface. SPRi in 
conjunction with signal amplification probes was further employed in the development of 
a highly selective steroid sensor that relies on x-aptamers as capture ligands. This 
bioassay not only achieved low limits of detection (> 1nM), but also demonstrated high 
selectivity to only progesterone.  
We anticipate that the analytical potential of SPRi will continue to provide 
insightful understanding to the interaction between different biomolecules in complex 
matrices. We also foresee tremendous impact on the medical diagnostic field as this 
optical assay reaches the lab-on-a chip point of care devices and carries out high 
throughput screening of an array of biological molecules.  
  Developments in instrumentation for a better resolution analysis are possible 
future trends of label-free analysis and merging advanced microfluidics to make the 
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detection highly reliable and efficient is another trend. Moreover, the detection of 
biomolecular interactions has begun and is expected to continue to merge with other 
analytical tools such as Mass Spectrometry, Raman Spectroscopy, Atomic Force 
Microscopy and many more to increase the efficacy of analysis of the bio-affinity of a 
variety of biomolecules. Improvements will also extend to cover further optimization to 
the sensor surface and ligand immobilization, which still requires better systematic 
strategies that lead to reproducible results. For this purpose, immobilization microarray 
spotting instruments exploited for ligand spotting will be further optimized for 
homogeneous spotted surfaces with little to no variability between density and biological 
activity of the different spotted ligands.  
SPRi analysis is also emerging as a sensitive platform to the areas of cellular 
interactions and processes at the single cell level [17, 116-118]. This label-free tool 
overcomes the challenges posed by colorimetric assays that cannot discriminate between 
bulk cellular activity and single cell [119]. This is expected to combine with other 
techniques such as fluorescence [120] and Raman analysis to increase the understanding 
of cellular mechanisms and solve outstanding problems in the biomedical field. 
Therefore, the knowledge obtained of cellular analysis can be combined with biomarker 
analysis to provide a more comprehensive understanding of various disease processes and 
highlight possible therapeutic routes for treatment.   
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